Existent proliferative responses of peripheral blood mononuclear cells from healthy donors and ovarian cancer patients to HER-2 peptides

Anticancer Research

Volumn 17, Issue 1 A, 1997, Pages 45-53

  Fisk, Bryan ^a   Hudson, J Michael ^a   Kavanagh, John ^a   Wharton, J Taylor ^a   Murray, James Lee ^a   Ioannides, Constantin G ^a   Kudelka, Andrzej P ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

CD4+; Cytokines; Epitope; HER 2; Ovarian cancer; Th1; Th2

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; ONCOPROTEIN; TUMOR ANTIGEN;

AMINO ACID SEQUENCE; ARTICLE; AUTOIMMUNITY; CELL PROLIFERATION; CELL SECRETION; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; MONONUCLEAR CELL; ONCOGENE NEU; OVARY CANCER; PRIORITY JOURNAL; T LYMPHOCYTE;

AMINO ACID SEQUENCE; CYTOKINES; FEMALE; HUMANS; LYMPHOCYTE ACTIVATION; MOLECULAR SEQUENCE DATA; OVARIAN NEOPLASMS; RECEPTOR, ERBB-2; T-LYMPHOCYTES;

EID: 0031049441     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Disis ML, Callenoff E, McLaughlin G, Murphy AE, Chen W, Groner B, Jeschke M, Lydon N, McGlynn E, Livingston RB, Moe R, and Cheever MA: Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 54: 16-20, 1994.
2. Ioannides CG, Fisk B, Fan D, Biddison WA, Wharton JT, and O'Brian CA, Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptides derived from the HER-2/neu proto-oncogene. Cell Immunol 151: 225-234, 1993.
3. Yoshino I, Goedegeboure PS, Peoples GE, Parikh AS, DiMain JM, Lyerly HK, Gazdar AF, and Eberlein TJ: HER-2/neu derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. Cancer Res 54: 3387-3390, 1994.
4. Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, and Eberlein TJ: Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc.Natl.Acad.Sci. USA 92: 432-436, 1995.
5. Fisk B, Blevins TL, Wharton JT, and Ioannides CG: Identification of an immunodominant peptide of HER-2/neu-proto-oncogene recognized by ovarian tumor specific CTL lines. J Exp Med 181: 2709-2717, 1995.
6. Ioannides CG, Platsoucas CD, and Freedman RS: Immunological effects of tumor vaccines II. T cell responses directed against cellular antigens in the viral oncolysates. In Vivo 4: 17-24, 1990
7. Falk K, Rotzschke O, Stevanovic S, Jung G, and Rammensee H-G: Pool sequencing of natural HLA-DR, DQ, and DP ligands reveals detailed peptide motifs, constrainsts of processing, and general rules. Immunogenetics 39: 230-242, 1994.
8. Kropshofer H, Max H, Muller CA, Hesse F, Stevanovic S, Jung G, and Kalbacher H: Self-peptide released from class II HLA-DRl exhibits a hydrophobic two-residue contactmotif. J Exp Med 175: 1799-1803, 1992.
9. Malcherek G, Falk K, Rotzschke O, Rammensee H-G, Stevanovic S, Gnau V, Jung G, and Melms A: Natural peptide ligand motifs of two HLA molecules associated with myastenia gravis. Int Immunol 5: 1229-1237, 1993.
10. Sette A, Sidney J, Oseroff C, del Guercio M-F, Southwood S, Arrheuius T, Powell MF, Colon SM, Graeta FCA, and Grey HG: HLA Drw4-binding motifs illustrate the biochemical basis of degeneracy and specificity in peptide-DR interactions. J Immunol 151: 3136-3170, 1993.
11. Hammer J, Valsasnini P, Tolba K, Bolin D, Higelin J, Takacs B, and Sinigaglia F: Promiscuous and allele-specific anchors in HLA-DR binding peptides. Cell 74: 197-203, 1993.
12. Hammer J, Gallazzi F, Bono E, Karr RW, Guenot J, Valsasnini P, Nagy ZA, and Sinigaglia F: Peptide binding specificity of HLA-DR4 molecules: Correlation with rheumatoid arthritis association. J Exp Med 181: 1847-1855, 1995.
13. Sinigaglia F, and Hammer J: Motifs and supermotifs for MHC class II binding peptides. J Exp Med 181: 449-451, 1995.
14. Marshall KW, Wilson KJ, Liang J, Woods A, Zaller D, and Rothbard JB: Prediction of peptide affinity to HLA-DRBI*0401. J Immunol 154: 5927-5933, 1995.
15. Barker RN, and Elson CJ: Multiple self epitopes on the Rhesus polypeptides stimulate immunologically ignorant human T cells. Eur J Immunol 24: 1578-1582, 1994.
16. Elson CJ, Barker RN, Thompson SJ, and Williams NA: Immunologically ignorant autoreactive T cells, epitope spreading and repertoire limitation. Immunol Today 16: 71-76, 1995.
17. + cell response against human immunodeficiency virus: Implication for longterm survival. Proc Natl Acad Sci USA 92: 11135-11139, 1995.
18. + T-cell responses to human myelin. Proc. Natl Acad Sci USA 91: 10859-10863, 1994.
19. Salgame P, Abrams JS, Clayberger C, Goldstein H, Convit J, Modlin RL, and Bloom BR: Differing lymophokine proflles of functional subsets of human CD4 and CD8 T cell clones. Science (Wash. DC) 254: 279-282, 1991.
20. Matsuda M, Salazer F, Petersson M, Masucci G, Hunsson T, Pisa P, Zhang, QJ, Masucci MG and Kiessling R: Interleukin 10 pretreatment protects target cells from tumor- and allele-specific cytotoxic T cells and downregulates HLA class I expression. J Exp Med 180: 2371-2376, 1994.
21. Croft M, Certer L, Swain SL, and Dutton RW: Generation of polarized antigenspeciflc CD8 effector populations: reciprocal action of interleukin (IL)-4 and IL-12 in promoting type 2 versus type I cytokine profiles. J Exp Med 180: 1715-1728, 1994.
22. Allison JP, Hurwitz AA, and Leach DR: Manipulation of costimulatory signals to enahnce antitumor T-cell responses. Curr Opin Immunol 7: 682-686, 1995.
23. Wu T-C, Guarnieri FG, Staveley-O'CarroIl KF, Viscidi RP, Levistsky HI, Hedrick L, Cho KR, August JT, and Pardoll DM. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci, USA 92: 11671-11675, 1995.
24. + T cells speciflcally recognize a shared melanomaassociated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci USA 91: 9461-9465, 1994.
25. Nanda NK and Sercarz EE: Induction of anti-self-immunity to cure cancer. Cell 82: 13-17, 1995.
26. Wucherpfennig KW, and Strominger JL: Selective binding of self peptides to diseaseassociated major histocompatibility complex (MHC) molecules: a mechanism for MHC-linked susceptibility to human autoimmune diseases. J Exp Med 181: 1597-1601, 1995.
27. Pfeiffler C, Stein J, Southwood S, Ketelaar H, Sette A, and Bottomly K: Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo. J Exp Med 181: 1569-1574, 1995.
28. Kumar V, Bheardwaj V, Soares L, Alexander J, Sette A, and Sercarz E: MHC binding affinity of an antigenic determinant is crucial for the differential secretion of IL4/5 or IFN γ by T cells. Proc Natl Acad Sci USA 92: 9510-9514, 1995.
29. Wucherpfennig KW and Strominger JL: Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific fur myelin basic protein. Cell 80: 695-705, 1995.
30. Silver RF, Wallis RS, and Ellner JJ: Mapping of T cell epitopes of the 30-kDa α antigen of mycobacterium bovis strain bacillus Calmette-Guerin in purified protein derivative (PPD)-positive individuals. J Immunol 154: 4665-4674, 1995.
31. Clerici M, and Shearer GM. The Th1 - Th2 hypothesis of HIV infection: new insights. Immunology Today 15: 575-581, 1994.
32. Sheen-Chen S-M, Chou F-F, Eng H-L, and Chen W-J: An evaluation of the prognostic signiflcance of HLA-DR expression in axillarynode-negative breast cancer. Surgery 116: 510-515, 1994.
33. Iarygin LM, Malyshev VS, Polianskaia IS, Denisov LE, Zimin II, Alekseeva PL, and Khotchenknoa NV. The clinical significance of determining the HLA-DR4 antigen in patients with breast cancer. Voprosy Onkologii 37: 796-799, 1991.
34. Casoli C, Zanelli P, Adorni A, Starcich BR, and Neri, T: Serological and molecular study on the HLA phenotype of female breast cancer patients Eur. J. Cancer 30: 1207-1208, 1994.
35. Lee JE, Reveille JD, Ross MI, and Platsoucas CD: HLA-DQBI*0301 association with increased cutaneous melanoma risk. Int. J. Cancer 59: 510-513, 1994.
36. Apple RJ, Erlich HA, Klitz W, Manos MM, Becker TM, Wheeler CM: HLA DR-D9 association with cervical carcinoma show papillomavirus-type speciflcity. Nature Genetics 6: 157-162, 1994.
37. + T lymphocytes against human melanoma. J Immunol 154: 772-779, 1995.
38. Topalian SL, Rivoltini L, Mancini M: Human CD4+ T cells specifically recognize a shared melanomas-associated antigen encoded by the tyrosinase gene. Proc. Natl. Acad. Sci. USA 91:9461-9465, 1994.
39. Becker JC, Brabletz T, Czemy C, Termeer C, and Brocker EB: Tumor escape mechanisms from immunosurvcillance: induction of unresponsiveness in a specific MHC-restricted CD4+ human T cell clone by the autologous MHC class II+ melanoma. International Immunology 5: 1501-1508, 1993.
40. Matsuo H, Batocchi A-P, Hawke S, Nicolle M, Jacobson L, Vincent A, Newsom-Davis J, and Willcox N: Peptide-selected T cell lines from mysastenia gravis patients and controls recognize epitopes that are not processed from whole acetylcholine receptor. J Immunol 155: 3683-3692, 1995.
41. Ioannides CG, and Freedman RS: T cell responses to ovarian tumor vaccines. International Reviewsof Immunology 7: 349-364, 1991.
42. Dong R-P, Kamikawaji N, Toida N, Fujita Y, Kimura A and Sasazuki T. Characterization of T cell epitopes restricted by HLA-DP9 in streptococcal M 12 protein. J Immunol 154: 4536-4545, 1995.